KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Enterprise Value (2016 - 2025)

Biogen has reported Enterprise Value over the past 17 years, most recently at -$3.8 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$3.8 billion for Q4 2025, down 60.66% from a year ago — trailing twelve months through Dec 2025 was -$3.8 billion (down 60.66% YoY), and the annual figure for FY2025 was -$3.8 billion, down 60.66%.
  • Enterprise Value for Q4 2025 was -$3.8 billion at Biogen, up from -$4.0 billion in the prior quarter.
  • Over the last five years, Enterprise Value for BIIB hit a ceiling of -$1.0 billion in Q4 2023 and a floor of -$6.1 billion in Q2 2023.
  • Median Enterprise Value over the past 5 years was -$2.7 billion (2025), compared with a mean of -$3.2 billion.
  • Biggest five-year swings in Enterprise Value: surged 78.73% in 2024 and later tumbled 141.84% in 2025.
  • Biogen's Enterprise Value stood at -$3.7 billion in 2021, then tumbled by 31.11% to -$4.9 billion in 2022, then skyrocketed by 78.58% to -$1.0 billion in 2023, then crashed by 126.21% to -$2.4 billion in 2024, then tumbled by 60.66% to -$3.8 billion in 2025.
  • The last three reported values for Enterprise Value were -$3.8 billion (Q4 2025), -$4.0 billion (Q3 2025), and -$2.8 billion (Q2 2025) per Business Quant data.